FDA
-
-
-
-
-
-
-
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
-
-
-
-
-
-
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Why public perception matters so much for biotech valuations
-
-
-
-
-
-
-
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
-
-
-
-
-
-
Alnylam Pharma (ALNY) Announces FDA Approval of Qfitlia
-
330,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

